These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2860024)

  • 21. Evaluation of alpha-cell function by infusion of alanine in normal, diabetic and obese subjects.
    Wise JK; Hendler R; Felig P
    N Engl J Med; 1973 Mar; 288(10):487-90. PubMed ID: 4567490
    [No Abstract]   [Full Text] [Related]  

  • 22. Hunger--a common symptom of hypoglycemia.
    Bernstein RK
    Diabetes Care; 1993 Jul; 16(7):1049. PubMed ID: 8359103
    [No Abstract]   [Full Text] [Related]  

  • 23. [Plasma glucagon and insulin profile in obese non-diabetic and non-insulin-dependent diabetic patients on a daily 800 calorie diet].
    Balázsi I; Varsányi-Nagy M; Nagy K
    Orv Hetil; 1986 Aug; 127(33):2009-13. PubMed ID: 3537903
    [No Abstract]   [Full Text] [Related]  

  • 24. The inhibitory effect of somatostatin on growth hormone, insulin and glucagon secretion in diabetes mellitus.
    Ward FR; Leblanc H; Yen SS
    J Clin Endocrinol Metab; 1975 Sep; 41(3):527-32. PubMed ID: 1159060
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of insulin on fasting and meal-stimulated somatostatin-like immunoreactivity in noninsulin-dependent diabetes mellitus: evidence for more than one mechanism of action.
    Gutniak M; Grill V; Efendić S
    J Clin Endocrinol Metab; 1986 Jan; 62(1):77-83. PubMed ID: 2866196
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Abnormal alpha cell function in human diabetes: the response to oral protein.
    Raskin P; Aydin I; Yamamoto T; Unger RH
    Am J Med; 1978 Jun; 64(6):988-97. PubMed ID: 350047
    [No Abstract]   [Full Text] [Related]  

  • 27. Effect of a 12-hour subcutaneous infusion of somatostatin-14 on blood glucose, insulin and glucagon levels in healthy subjects and insulin dependent diabetics.
    Villaume C; Beck B; Kolopp M; Toussain P; Debry G
    Biomed Pharmacother; 1986; 40(2):61-4. PubMed ID: 2875745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Twenty-four-hour somatostatin infusions in normals, juvenile diabetics, and maturity-onset diabetics.
    Christensen SE; Hansen AP; Orskov H; Lundbaek K
    Metabolism; 1978 Sep; 27(9 Suppl 1):1427-31. PubMed ID: 683011
    [No Abstract]   [Full Text] [Related]  

  • 29. Determination of pancreatic and gut glucagon-like immunoreactivity (GLI) in normal and diabetic subjects.
    Heding LG; Rasmussen SM
    Diabetologia; 1972 Dec; 8(6):408-11. PubMed ID: 4675088
    [No Abstract]   [Full Text] [Related]  

  • 30. Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus. Accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion.
    Campbell PJ; Bolli GB; Cryer PE; Gerich JE
    N Engl J Med; 1985 Jun; 312(23):1473-9. PubMed ID: 2859524
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of gastric emptying as a therapeutic approach to glycaemic control.
    Moyses C; Young A; Kolterman O
    Diabet Med; 1996 Sep; 13(9 Suppl 5):S34-8. PubMed ID: 8894469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Significance of glucagon in the pathogenesis of diabetes (a review)].
    Kendysh IN
    Vopr Med Khim; 1981; 27(2):147-54. PubMed ID: 6116354
    [No Abstract]   [Full Text] [Related]  

  • 33. [Glucagon response to a high protein meal in normal and diabetic subjects (author's transl)].
    Ruiz F; Durruty P; Mella I; García de los Rios M
    Rev Med Chil; 1978 Dec; 106(12):973-8. PubMed ID: 556366
    [No Abstract]   [Full Text] [Related]  

  • 34. Somatostatin receptor subtype-2-deficient mice with diet-induced obesity have hyperglycemia, nonfasting hyperglucagonemia, and decreased hepatic glycogen deposition.
    Singh V; Grötzinger C; Nowak KW; Zacharias S; Göncz E; Pless G; Sauer IM; Eichhorn I; Pfeiffer-Guglielmi B; Hamprecht B; Wiedenmann B; Plöckinger U; Strowski MZ
    Endocrinology; 2007 Aug; 148(8):3887-99. PubMed ID: 17525126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathophysiology of diabetes mellitus.
    Sherwin R; Felig P
    Med Clin North Am; 1978 Jul; 62(4):695-711. PubMed ID: 682722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two compartment pharmacodynamics of somatostatin in non-obese non-insulin-dependent diabetes.
    Wang JT; Ho LT; Tang KT; Lam HC; Wang LM; Ching KN
    Zhonghua Yi Xue Za Zhi (Taipei); 1987 Dec; 40(6):505-10. PubMed ID: 2901899
    [No Abstract]   [Full Text] [Related]  

  • 37. [The insulin and proinsulin levels in patients with newly detected diabetes mellitus].
    Arbuzova MI; Lobanova AM; Smirnova OM; Antsiferov MB; Starostina EG
    Probl Endokrinol (Mosk); 1989; 35(5):28-31. PubMed ID: 2685803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Indomethacin does not affect endogenous glucose production in type 2 diabetes mellitus.
    Pereira Arias AM; Bisschop PH; Ackermans MT; Endert E; Romijn JA; Sauerwein HP
    Horm Metab Res; 2001 Nov; 33(11):659-63. PubMed ID: 11733868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic effects of somatostatin in maturity-onset diabetes.
    Tamborlane WV; Sherwin RS; Hendler R; Felig P
    N Engl J Med; 1977 Jul; 297(4):181-3. PubMed ID: 876274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus.
    Hare KJ
    Dan Med Bull; 2010 Sep; 57(9):B4181. PubMed ID: 20816021
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.